Mn Services Vermogensbeheer B.V. Sells 3,600 Shares of Cencora, Inc. (NYSE:COR)

Mn Services Vermogensbeheer B.V. decreased its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 5.4% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 62,900 shares of the company's stock after selling 3,600 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Cencora were worth $17,492,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. JFS Wealth Advisors LLC lifted its position in shares of Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after acquiring an additional 46 shares in the last quarter. Hoey Investments Inc. bought a new position in Cencora in the 1st quarter worth approximately $28,000. Banque Transatlantique SA purchased a new stake in Cencora during the 4th quarter valued at approximately $29,000. SBI Securities Co. Ltd. bought a new stake in shares of Cencora during the fourth quarter valued at approximately $30,000. Finally, WASHINGTON TRUST Co grew its stake in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after acquiring an additional 46 shares in the last quarter. Institutional investors own 97.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on COR. Bank of America raised their target price on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Morgan Stanley set a $288.00 price objective on shares of Cencora in a research note on Tuesday, April 15th. Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Citigroup increased their price target on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Finally, UBS Group lifted their price target on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Cencora presently has an average rating of "Moderate Buy" and an average price target of $306.91.

Cencora Stock Up 0.0%

NYSE COR opened at $295.12 on Monday. The business has a fifty day moving average price of $287.24 and a 200 day moving average price of $261.82. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The company has a market cap of $57.20 billion, a P/E ratio of 41.98, a P/E/G ratio of 1.31 and a beta of 0.58. Cencora, Inc. has a one year low of $218.65 and a one year high of $309.35.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. During the same quarter last year, the firm earned $3.80 earnings per share. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. Research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date was Friday, May 16th. Cencora's dividend payout ratio is currently 25.52%.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the transaction, the chief executive officer now owns 47,582 shares in the company, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the completion of the transaction, the chairman now owns 315,913 shares of the company's stock, valued at $89,027,442.53. This represents a 4.41% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,253 shares of company stock worth $10,582,297. Company insiders own 10.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.